Applied Health Economics and Health Policy

2008 - 2025

Current editor(s): Timothy Wrightson

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 17, issue 6, 2019

Expanding the Role of the Patient-Centered Outcomes Research Institute: Reauthorization and Facilitating Value Assessments pp. 757-759

William V. Padula and R. Brett McQueen

A Framework to Prioritise Health Research Proposals for Funding: Integrating Value for Money pp. 761-770

Haitham W. Tuffaha, Joanne Aitken, Suzanne Chambers and Paul Scuffham

A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments pp. 771-780

Ash Bullement, Holly L. Cranmer and Gemma E. Shields

A Review of the Development and Application of Generic Preference-Based Instruments with the Older Population pp. 781-801

Jenny Cleland, Claire Hutchinson, Jyoti Khadka, Rachel Milte and Julie Ratcliffe

Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries pp. 803-816

Sabine Vogler, Guillaume Dedet and Hanne Bak Pedersen

The Value Employees Place on Health Insurance Plans: A Discrete-Choice Experiment pp. 817-825

Stephen Poteet and Benjamin M. Craig

Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting pp. 827-839

Gabriel Tremblay, Ben Rousseau, Miriam Marquis, Cyrielle Beaubois, Guy Sauvageau and Josée Hébert

Using Adherence-Contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial pp. 841-855

Marcel Bilger, Tina T. Wong, Jia Yi Lee, Kaye L. Howard, Filipinas G. Bundoc, Ecosse L. Lamoureux and Eric A. Finkelstein

Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands pp. 857-873

Renée Else Michels, Maria Fransesco, Koshu Mahajan, Gerald J. D. Hengstman, Krijn M. H. Schiffers, Sangeeta Budhia, Gerard Harty and Marieke Krol

In-Hospital Healthcare Utilization, Outcomes, and Costs in Pre-Hospital-Adjudicated Low-Risk Chest-Pain Patients pp. 875-882

Dominique N. Dongen, Jan Paul Ottervanger, Rudolf Tolsma, Marion Fokkert, Aize Sluis, Arnoud W. J. ‘t Hof, Erik Badings and Robbert J. Slingerland

Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia pp. 883-893

Rick A. Vreman, Joost W. Geenen, Anke M. Hövels, Wim G. Goettsch, Hubert G. M. Leufkens and Maiwenn J. Al

What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population pp. 895-902

Kim Pauwels, Isabelle Huys, Minne Casteels, Yvonne Denier, Martina Vandebroek and Steven Simoens

Volume 17, issue 5, 2019

Health Technology Assessment as Part of a Broader Process for Priority Setting and Resource Allocation pp. 573-576

Craig Mitton, Brayan V. Seixas, Stuart Peacock, Michael Burgess and Stirling Bryan

Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers pp. 577-590

Simon Walker, Susan Griffin, Miqdad Asaria, Aki Tsuchiya and Mark Sculpher

A Systematic Review of Productivity in Economic Evaluations of Workplace Interventions: A Need for Reporting Criteria? pp. 591-613

Cheryl Jones, Suzanne M. M. Verstappen and Katherine Payne

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16) pp. 615-627

Richard F. Pollock, William J. Valentine, Steven P. Marso, Andreas Andersen, Jens Gundgaard, Nino Hallén, Deniz Tutkunkardas, Elizabeth A. Magnuson and John B. Buse

The Economic Burden of Asthma in Greece: A Cross-Sectional Study pp. 629-640

Katerina Vellopoulou, Petros Bakakos, Stelios Loukides, Nikos Maniadakis and Georgia Kourlaba

Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy pp. 641-654

Shui Ling Wong, Saliza Ibrahim, Norazlin Abdul Kadir and Salbiah Mohd Salleh

Budget Impact Analysis of Molecular Lymph Node Staging Versus Conventional Histopathology Staging in Colorectal Carcinoma pp. 655-667

Sherley Diaz-Mercedes, Ivan Archilla, Jordi Camps, Antonio Lacy, Iñigo Gorostiaga, Dulce Momblan, Ainitze Ibarzabal, Joan Maurel, Nuria Chic, Josep Antoni Bombí, Francesc Balaguer, Antoni Castells, Iban Aldecoa, Josep Maria Borras and Miriam Cuatrecasas

Cost-Effectiveness of a Psycho-Educational Intervention Targeting Fear of Cancer Recurrence in People Treated for Early-Stage Melanoma pp. 669-681

Mbathio Dieng, Nikita Khanna, Nadine A. Kasparian, Daniel S. J. Costa, Phyllis N. Butow, Scott W. Menzies, Graham J. Mann, Anne E Cust and Rachael L. Morton

Developing Attributes and Attribute-Levels for a Discrete-Choice Experiment: An Example for Interventions of Impulsive Violent Offenders pp. 683-705

Stella Nalukwago Settumba, Marian Shanahan, Tony Butler, Peter Schofield, Lise Lafferty, Paul Simpson and Georgina M. Chambers

General Trends in Prices and Prescription Patterns of Anticonvulsants in Germany between 2000 and 2017: Analysis of National and Cohort-Based Data pp. 707-722

Laurent M. Willems, Hajo M. Hamer, Susanne Knake, Felix Rosenow, Jens-Peter Reese and Adam Strzelczyk

Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults pp. 723-732

Ashleigh McGirr, Desiree Van Oorschot, Robyn Widenmaier, Michael Stokes, Michael L. Ganz, Hyosung Jung, Lijoy Varghese and Desmond Curran

Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA pp. 733-740

Lotte Steuten, Vincent Garmo, Hemant Phatak, Sean D. Sullivan, Paul Nghiem and Scott D. Ramsey

A Probe into the Wages and Salaries of Health Economics, Outcomes Research, and Market Access Professionals pp. 741-751

Manuel J. Carvajal, Patti Peeples and Ioana Popovici

Volume 17, issue 4, 2019

Why is There Discordance between the Reimbursement of High-Cost ‘Life-Extending’ Pharmaceuticals and Medical Devices? The Funding of Ventricular Assist Devices in Australia pp. 421-431

Sopany Saing, Naomi van der Linden, Christopher Hayward and Stephen Goodall

Advanced Data Visualisation in Health Economics and Outcomes Research: Opportunities and Challenges pp. 433-441

Shelagh M. Szabo, Karissa M. Johnston and Andrew J. Lloyd

A Review of the Challenges of Using Biomedical Big Data for Economic Evaluations of Precision Medicine pp. 443-452

Patrick Fahr, James Buchanan and Sarah Wordsworth

Mepilex Border Sacrum and Heel Dressings for the Prevention of Pressure Ulcers: A NICE Medical Technology Guidance pp. 453-465

C. Marshall, J. Shore, M. Arber, M. Cikalo, T. Oladapo, A. Peel, R. McCool and Michelle Jenks

Systematic Review of Decision Analytic Modelling in Economic Evaluations of Low Back Pain and Sciatica pp. 467-491

James A. Hall, Kika Konstantinou, Martyn Lewis, Raymond Oppong, Reuben Ogollah and Sue Jowett

Budget Impact Analysis of Cancer Screening: A Methodological Review pp. 493-511

Beate Jahn, Jovan Todorovic, Marvin Bundo, Gaby Sroczynski, Annette Conrads-Frank, Ursula Rochau, Gottfried Endel, Ingrid Wilbacher, Nikoletta Malbaski, Niki Popper, Jagpreet Chhatwal, Dan Greenberg, Josephine Mauskopf and Uwe Siebert

The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration pp. 513-521

Risha Gidwani-Marszowski, Douglas K. Owens, Jeanie Lo, Jeremy D. Goldhaber-Fiebert, Steven M. Asch and Paul G. Barnett

Physical Activity and Healthcare Costs: Projections for Poland in the Context of an Ageing Population pp. 523-532

Małgorzata Kalbarczyk and Joanna Mackiewicz-Łyziak

Applying an Implementation Framework to the Use of Evidence from Economic Evaluations in Making Healthcare Decisions pp. 533-543

Gregory Merlo, Katie Page, Pauline Zardo and Nicholas Graves

Willingness to Pay for Cataract Surgeries Among Patients Visiting Eye Care Facilities in Dhaka, Bangladesh pp. 545-554

Muhammed Nazmul Islam, Thomas Engels, Shafayet Hossain, Malabika Sarker and Atonu Rabbani

Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia pp. 555-567

Carsten Hirt, Sergio Iannazzo, Silvia Chiroli, Lisa J. McGarry, Philipp Coutre, Leif Stenke, Torsten Dahlén and Jeffrey H. Lipton

Comment on: “Cost Effectiveness of Dialysis Modalities: A Systematic Review of Economic Evaluations” pp. 569-570

Salman Hussain, Ambrish Singh, Anwar Habib, Md Sarfaraj Hussain and Abul Kalam Najmi

Authors’ Reply to Hussain et al.: “Cost Effectiveness of Dialysis Modalities: A Systematic Review of Economic Evaluations” pp. 571-572

Martin Howell, Rachael Walker and Kirsten Howard

Volume 17, issue 3, 2019

Vaccination: Is There a Place for Penalties for Non-compliance? pp. 265-271

Tracey Chantler, Emilie Karafillakis and James Wilson

The Value of Further Research: The Added Value of Individual-Participant Level Data pp. 273-284

Pedro Saramago, Manuel A. Espinoza, Alex J. Sutton, Andrea Manca and Karl Claxton

Thopaz+ Portable Digital System for Managing Chest Drains: A NICE Medical Technology Guidance pp. 285-294

James Michael Evans, Alistair Ray, Megan Dale, Helen Morgan, Paul Dimmock and Grace Carolan-Rees

An Updated Systematic Review of Studies Mapping (or Cross-Walking) Measures of Health-Related Quality of Life to Generic Preference-Based Measures to Generate Utility Values pp. 295-313

Clara Mukuria, Donna Rowen, Sue Harnan, Andrew Rawdin, Ruth Wong, Roberta Ara and John Brazier

Cost Effectiveness of Dialysis Modalities: A Systematic Review of Economic Evaluations pp. 315-330

Martin Howell, Rachael C. Walker and Kirsten Howard

Economic Evaluations of Childhood Hearing Loss Screening Programmes: A Systematic Review and Critique pp. 331-357

Rajan Sharma, Yuanyuan Gu, Teresa Y. C. Ching, Vivienne Marnane and Bonny Parkinson

The Association Between Adiposity and Inpatient Hospital Costs in the UK Biobank Cohort pp. 359-370

Padraig Dixon, George Davey Smith and William Hollingworth

Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models pp. 371-380

Lan Gao and Shu-Chuen Li

A Payer Perspective of the Hospital Inpatient Additional Care Costs of Antimicrobial Resistance in France: A Matched Case–Control Study pp. 381-389

Mehdi Touat, Marion Opatowski, Christian Brun-Buisson, Kristel Cosker, Didier Guillemot, Jerome Salomon, Philippe Tuppin, Gregoire de Lagasnerie and Laurence Watier

Reducing Drug Wastage in Pharmaceuticals Dosed by Weight or Body Surface Areas by Optimising Vial Sizes pp. 391-397

Anthony J. Hatswell and Joshua K. Porter

A Transparent Universal Health Coverage Index with Decomposition by Socioeconomic Groups: Application in Asian and African Settings pp. 399-410

Jahangir A. M. Khan, Sayem Ahmed, Tao Chen, Ewan M. Tomeny and Louis W. Niessen

Using Post-market Utilisation Analysis to Support Medicines Pricing Policy: An Australian Case Study of Aflibercept and Ranibizumab Use pp. 411-417

Anna Kemp-Casey, Nicole Pratt, Emmae Ramsay and Elizabeth E. Roughead

Correction to: Economic Evaluations of Childhood Hearing Loss Screening Programmes: A Systematic Review and Critique pp. 419-419

Rajan Sharma, Yuanyuan Gu, Teresa Y. C. Ching, Vivienne Marnane and Bonny Parkinson

Volume 17, issue 2, 2019

Re-design of Aged Care Environments is Key to Improved Care Quality and Cost Effective Reform of Aged and Health System Care pp. 127-130

Simon Eckermann, Lyn Phillipson and Richard Fleming

ReCell® Spray-On Skin System for Treating Skin Loss, Scarring and Depigmentation after Burn Injury: A NICE Medical Technology Guidance pp. 131-141

Susan Caroline Peirce and Grace Carolan-Rees

Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review pp. 143-162

Dominik J. Wettstein and Stefan Boes

Family Spillover Effects in Pediatric Cost-Utility Analyses pp. 163-174

Tara A. Lavelle, Brittany N. D’Cruz, Babak Mohit, Wendy J. Ungar, Lisa A. Prosser, Kate Tsiplova, Montserrat Vera-Llonch and Pei-Jung Lin

The Effect of Medical Insurance on Outpatient Visits by the Elderly: An Empirical Study with China Health and Retirement Longitudinal Study Data pp. 175-187

Chunjuan Qiu and Xianyi Wu

Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies Guidance pp. 189-211

Francisca Crispi, Huseyin Naci, Eva Barkauskaite, Leeza Osipenko and Elias Mossialos

Cost Effectiveness of New Diagnostic Tools for Cutaneous Leishmaniasis in Afghanistan pp. 213-230

Céline Aerts, Martijn Vink, Sayed Jalal Pashtoon, Sami Nahzat, Albert Picado, Israel Cruz and Elisa Sicuri

Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers’ Compensation System pp. 231-242

Leslie Wilson, Fatema Turkistani, Dang M. Tran, Wei Huang and Tracy Kuo Lin

Real-World Cost Effectiveness of Mandatory Folic Acid Fortification of Bread-Making Flour in Australia pp. 243-254

Sopany Saing, Philip Haywood, Naomi van der Linden, Kathleen Manipis, Elena Meshcheriakova and Stephen Goodall

Comment on: “The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review” pp. 255-256

Carlos Vílchez-Román, Sol Sanguinetti and Edward Mezones-Holguín

Comment on: “Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model” pp. 257-258

Paul Mintz

Authors’ Reply to Mintz: “Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model” pp. 259-261

Laura T. Pizzi, Katherine M. Prioli and Jay H. Herman

Correction to: Use of Expert Judgement Across NICE Guidance‑Making Programmes: A Review of Current Processes and Suitability of Existing Tools to Support the Use of Expert Elicitation pp. 263-264

Alison Peel, Michelle Jenks, Moni Choudhury, Rosemary Lovett, Juan Carlos Rejon‑Parrilla, Andrew Sims and Joyce Craig

Volume 17, issue 1, 2019

Ethically Acceptable Compensation for Living Donations of Organs, Tissues, and Cells: An Unexploited Potential? pp. 1-14

Trine Platz, Nikolaj Siersbæk and Lars Peter Østerdal

Standardized Questionnaire for the Measurement, Valuation, and Estimation of Costs of Informal Care Based on the Opportunity Cost and Proxy Good Method pp. 15-24

Erik Landfeldt, Niklas Zethraeus and Peter Lindgren

Peristeen Transanal Irrigation System to Manage Bowel Dysfunction: A NICE Medical Technology Guidance pp. 25-34

Megan Dale, Helen Morgan, Kimberly Carter, Judith White and Grace Carolan-Rees

A Systematic Review of Cost-Effectiveness Analyses of Left Ventricular Assist Devices: Issues and Challenges pp. 35-46

Jordana K. Schmier, Jasmine D. Patel, Megan J. Leonhard and Prem A. Midha

The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents pp. 47-54

Jonathan J. Darrow, Reed F. Beall and Aaron S. Kesselheim

Budget Impact Analysis of a Renal Point-of-Care Test in Dutch Community Pharmacies to Prevent Antibiotic-Related Hospitalizations pp. 55-63

Judith J. Gout-Zwart, Erien H. J. Olde Hengel, Petra Hoogland and Maarten J. Postma

Cost-Effectiveness of Scaling Up Modern Family Planning Interventions in Low- and Middle-Income Countries: An Economic Modeling Analysis in Indonesia and Uganda pp. 65-76

Neily Zakiyah, A. D. I. Asselt, D. Setiawan, Q. Cao, F. Roijmans and M. J. Postma

Trends and Factors Associated with Hospitalization Costs for Inflammatory Bowel Disease in the United States pp. 77-91

Fang Xu, Yong Liu, Anne G. Wheaton, Kristina M. Rabarison and Janet B. Croft

Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert System pp. 93-101

Irene Eriksson, Mia von Euler, Rickard E. Malmström, Brian Godman and Björn Wettermark

Reliability and Validity of the Contingent Valuation Method for Estimating Willingness to Pay: A Case of In Vitro Fertilisation pp. 103-110

Stella Nalukwago Settumba, Marian Shanahan, Willings Botha, Muhammad Zulilhaam Ramli and Georgina Mary Chambers

The Economic Burden of Chronic Obstructive Pulmonary Disease in Greece pp. 111-121

Georgia Kourlaba, Georgios Hillas, Theodoros Vassilakopoulos and Nikos Maniadakis

Comment on: “Does MCDA Trump CEA?” pp. 123-124

Aris Angelis and Panos Kanavos

Authors’ Reply to Angelis and Kanavos: “Does MCDA Trump CEA?” pp. 125-125

Carlos Campillo-Artero, Jaume Puig-Junoy and Anthony Culyer